NCT02542514View on ClinicalTrials.gov

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2015

Primary Completion Date

August 31, 2016

Study Completion Date

December 1, 2021

Conditions

Primary Central Nervous LymphomaIntraocular Lymphoma

Interventions

DRUG

Ibrutinib

p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)

Trial Locations (10)

Unknown

CHU d'ESTAING, Clermont-Ferrand

CHU de Grenoble, Grenoble

CHRU de LILLE - Claude Huriez, Lille

Centre Léon Bérard, Lyon

CHU de la Pitié Salpêtrière, Paris

CHU de la Timone, Paris

CHU de Rennes, Rennes

Centre Henri Becquerel, Rouen

Hôpital René Huguenin Institut Curie, Saint-Cloud

CHU Brabois, Vandœuvre-lès-Nancy

All Listed Sponsors

lead

The Lymphoma Academic Research Organisation

OTHER

NCT02542514 - Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma | Biotech Hunter | Biotech Hunter